163 related articles for article (PubMed ID: 36449764)
1. Total cholesterol/high-density lipoprotein and inflammatory parameters in patients with polycystic ovary syndrome.
Gülücü S; Can İS
Rev Assoc Med Bras (1992); 2022; 68(11):1499-1503. PubMed ID: 36449764
[TBL] [Abstract][Full Text] [Related]
2. Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome.
Glintborg D; Altinok M; Mumm H; Buch K; Ravn P; Andersen M
Hum Reprod; 2014 Aug; 29(8):1773-9. PubMed ID: 24903198
[TBL] [Abstract][Full Text] [Related]
3. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables.
Holte J; Bergh T; Berne C; Lithell H
Clin Endocrinol (Oxf); 1994 Oct; 41(4):463-71. PubMed ID: 7955457
[TBL] [Abstract][Full Text] [Related]
4. The monocyte counts to HDL cholesterol ratio in obese and lean patients with polycystic ovary syndrome.
Usta A; Avci E; Bulbul CB; Kadi H; Adali E
Reprod Biol Endocrinol; 2018 Apr; 16(1):34. PubMed ID: 29631598
[TBL] [Abstract][Full Text] [Related]
5. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
[TBL] [Abstract][Full Text] [Related]
6. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome.
Falsetti L; Pasinetti E
Acta Obstet Gynecol Scand; 1995 Jan; 74(1):56-60. PubMed ID: 7856434
[TBL] [Abstract][Full Text] [Related]
7. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment.
Pasquali R; Gambineri A; Anconetani B; Vicennati V; Colitta D; Caramelli E; Casimirri F; Morselli-Labate AM
Clin Endocrinol (Oxf); 1999 Apr; 50(4):517-27. PubMed ID: 10468913
[TBL] [Abstract][Full Text] [Related]
8. The effect of Curcumin on metabolic parameters and androgen level in women with polycystic ovary syndrome: a randomized controlled trial.
Ghanbarzadeh-Ghashti N; Ghanbari-Homaie S; Shaseb E; Abbasalizadeh S; Mirghafourvand M
BMC Endocr Disord; 2023 Feb; 23(1):40. PubMed ID: 36788534
[TBL] [Abstract][Full Text] [Related]
9. The influence of body weight on lipoprotein lipids in patients with polycystic ovary syndrome.
Wild RA; Bartholomew MJ
Am J Obstet Gynecol; 1988 Aug; 159(2):423-7. PubMed ID: 2970222
[TBL] [Abstract][Full Text] [Related]
10. Clinical and metabolic characteristics of polycystic ovary syndrome without polycystic ovary: a pilot study on Chinese women.
Shi Y; Gao X; Sun X; Zhang P; Chen Z
Fertil Steril; 2008 Oct; 90(4):1139-43. PubMed ID: 17889857
[TBL] [Abstract][Full Text] [Related]
11. Lipid profiles in women with hirsutism and polycystic ovaries.
Senöz S; Ozaksit G; Turhan NO; Gülekli B; Gökmen O
Gynecol Endocrinol; 1994 Mar; 8(1):33-7. PubMed ID: 8059615
[TBL] [Abstract][Full Text] [Related]
12. The Apolipoprotein B/A1 Ratio is Associated With Metabolic Syndrome Components, Insulin Resistance, Androgen Hormones, and Liver Enzymes in Women With Polycystic Ovary Syndrome.
He H; Feng J; Zhang S; Wang Y; Li J; Gao J; Cong J; Gong Y; Wu X
Front Endocrinol (Lausanne); 2021; 12():773781. PubMed ID: 35069437
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome.
Legro RS; Kunselman AR; Dunaif A
Am J Med; 2001 Dec; 111(8):607-13. PubMed ID: 11755503
[TBL] [Abstract][Full Text] [Related]
14. The Predictive Role of Serum Cystatin C Levels in Polycystic Ovary Syndrome in Adolescents.
Çınar M; Aksoy RT; Güzel Aİ; Tokmak A; Çandar T; Taşçı Y
J Pediatr Adolesc Gynecol; 2016 Aug; 29(4):353-6. PubMed ID: 26740281
[TBL] [Abstract][Full Text] [Related]
15. Polycystic ovaries in Hirsute women with normal menses.
Carmina E; Lobo RA
Am J Med; 2001 Dec; 111(8):602-6. PubMed ID: 11755502
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous Findings and Systemic Associations in Women With Polycystic Ovary Syndrome.
Schmidt TH; Khanijow K; Cedars MI; Huddleston H; Pasch L; Wang ET; Lee J; Zane LT; Shinkai K
JAMA Dermatol; 2016 Apr; 152(4):391-8. PubMed ID: 26720591
[TBL] [Abstract][Full Text] [Related]
17. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives.
Mastorakos G; Koliopoulos C; Creatsas G
Fertil Steril; 2002 May; 77(5):919-27. PubMed ID: 12009344
[TBL] [Abstract][Full Text] [Related]
18. Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome.
Gökmen O; Senöz S; Gülekli B; Işik AZ
Gynecol Endocrinol; 1996 Aug; 10(4):249-55. PubMed ID: 8908525
[TBL] [Abstract][Full Text] [Related]
19. Are serum chemerin levels different between obese and non-obese polycystic ovary syndrome women?
Yang S; Wang Q; Huang W; Song Y; Feng G; Zhou L; Tan J
Gynecol Endocrinol; 2016; 32(1):38-41. PubMed ID: 26291816
[TBL] [Abstract][Full Text] [Related]
20. Pregnancy complications and endometrial cancer in women with polycystic ovarian syndrome: a Korean National Health Insurance Service study.
Kim JH; Jung MH; Moon N; Hong SH; Kang DR
Int J Gynecol Cancer; 2023 Oct; 33(10):1580-1586. PubMed ID: 37479466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
